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Abstract
Background Two-thirds partial hepatectomy (PHx) is an
established model for the study of liver regeneration after
resection. This process is accompanied by oxidative stress.
Aims In our study, we tested the effect of epigallocate-
chin gallate (EGCG), a green tea antioxidant, on the early
phase of liver regeneration after PHx.
Methods Male Wistar rats were divided into five groups:
(I) laparotomy ? water for intraperitoneal injections, (II)
laparotomy ? EGCG 50 mg/kg body weight, (III)
PHx ? water for injections, (IV) PHx ? EGCG 20 mg/kg
and (V) PHx ? EGCG 50 mg/kg, for 3 consecutive days.
The rats were killed 24 h after surgery. Biochemical ana-
lysis of rat sera was performed. Histological samples were
stained with hematoxylin & eosin and bromodeoxyuridine
(BrdU). In hepatectomized rats, we also measured plasma
malondialdehyde, tissue malondialdehyde, glutathione and
cytokines levels, the activity of caspases 3/7, expression of
Nqo-1 and HO-1 genes at the mRNA level, and expression
of p21, p-p27 and p-p53 genes at the protein level.
Results We observed lower accumulation of BrdU in
group V when compared to groups III and IV. The activity
of caspases 3/7 and expression of p-p53 were lower in
group V than in groups III and IV. Tissue levels of IL-6
were lower in group V when compared to group III. Sig-
nificant differences were not noted in other parameters.
Conclusions Administration of EGCG did not stimulate
early phase liver regeneration in rats after PHx. There was
even lower DNA synthesis in the group treated with a high
dose of EGCG.
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EGCG20 Epigallocatechin gallate 20 mg/kg body
weight
EGCG50 Epigallocatechin gallate 50 mg/kg body
weight
GSH Glutathione (reduced form)
GSSG Glutathione (oxidized form)
HO-1 Heme oxygenase-1
HRR Hepatic regeneration rate [25]
IL-6 Interleukin-6
LAP Laparotomy
LRR Liver regeneration rate [26]
MDA Malondialdehyde
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Nqo-1 NAD(P)H-quinone-oxidoreductase
Nrf2-2 NF-E2-related factor 2
PHx Two-thirds partial hepatectomy
TGF-b1 Transforming growth factor beta1
TNF-a Tumor necrosis factor alpha
Introduction
Liver resection is a surgical procedure performed for a
variety of malignant and benign focal liver lesions. It is one
of the few methods that gives the patient a chance for
complete recovery. This is in both primary liver tumors,
especially hepatocellular carcinoma [1], and secondary
tumors, notably liver metastases from colorectal carcinoma
[2].
Vascular occlusion, used during liver resection to pre-
vent hemorrhage, causes ischemia–reperfusion injury.
Reperfusion of the liver enhances cell injury by oxidative
stress and an inflammatory reaction [3]. In addition, liver
regeneration itself was found to be a state of increased
oxidative stress [4, 5]. Some surgical procedures for pre-
venting the ischemia–reperfusion injury have already
found their way into clinical practice [3], whereas possible
pharmacological approaches remain limited. This is
because no decrease in mortality, incidence of liver failure
or perioperative morbidity was found [6]. Two-thirds par-
tial hepatectomy (PHx), carried out on small laboratory
animals, is a well-established model for studying of liver
regeneration [7].
Excessive oxidative stress observed in mice after
knockout of a key transcription factor for endogenous
antioxidative enzymes led to significant diminution of liver
regeneration after PHx [8]. This transcription factor, NF-
E2-related factor 2 (Nrf2), is an upstream regulator of
various antioxidative proteins and xenobiotic-metabolizing
enzymes, particularly glutathione-S-transferase, NAD(P)H-
quinone-oxidoreductase (Nqo-1), superoxide-dismutase,
glutathione-peroxidase, heme oxygenase-1 (HO-1), cata-
lase and others [8–10].
Protection against oxidative stress may enhance liver
regeneration after resection, as shown in a study using
vitamins C and E [11]. Aside from these directly acting
antioxidants, which after oxidation can act as pro-oxidants,
indirect antioxidants exist. These are able to activate the
aforementioned transcription factor Nrf2 and subsequently
many cytoprotective proteins [9, 10]. The indirectly acting
antioxidants have very low prooxidative effects [12].
One of these is (-)-epigallocatechin-3-gallate (EGCG),
a polyphenolic antioxidant from green tea. Besides this
effect, EGCG also acts as a direct antioxidant because of
the presence of phenolic groups that are sensitive to oxi-
dation and can generate quinone [9, 13]. EGCG is the most
abundant of the green tea catechins [14]. Its protective role
was found in a model of acute toxic liver injury [15],
chronic toxic liver injury [16, 17], non-alcoholic steatosis
and steatohepatitis [18–20], and hepatic ischemia–reper-
fusion injury [18, 21]. EGCG was also able to ameliorate
experimental diabetes mellitus by downregulation of genes
for gluconeogenesis and synthesis of fatty acids, triacyl-
glycerols and cholesterol [22, 23]. The effect of EGCG on
liver regeneration after PHx has not been tested yet.
In our study, we tested the effect of EGCG in the early
phase of liver regeneration after PHx in rats. Since the
highest rate of DNA synthesis is in hepatocytes 24 h after
PHx [24], we decided to investigate the regenerative
response in this particular interval. We also focused on the




Unless otherwise stated, BrdU (5-bromo-2-deoxyuridine)
and other chemicals used were all of analytical grade and
had been purchased from Sigma-Aldrich (St. Louis, MO,
USA). The kit for determination of caspase 3/7 activities
was obtained from Promega (Madison, WI, USA). Mouse
monoclonal anti-BrdU antibody had been obtained from
DAKO (Glostrup, Denmark) and secondary anti-mouse
antibody from Jackson ImmunoResearch Laboratories
(West Grove, PA, USA).
Mouse anti-b-actin antibodies and rabbit anti-p21 CIP1
were purchased from Sigma-Aldrich, rabbit p27 Kip1 and
rabbit phospho-p53 (Ser15) from Cell Signaling (Beverly,
MA, USA), mouse Bcl-2 antibody (C-2) from Santa Cruz
Biotechnology (Dallas, TX, USA), secondary goat anti-
rabbit IgG from Sigma-Aldrich and secondary goat anti-
mouse IgG from Santa Cruz Biotechnology.
Experimental Design
Male Wistar rats (BioTest, Kona´rovice, Czech Republic)
with initial weight of 248 ± 13 g were used throughout the
study. The rats were housed at 23 ± 1 C, 55 ± 10 %
humidity, air exchange 12–14 times/h and 12 h light–dark
cycles. The animals had free access to tap water and were
fed the standard pelleted diet ST-1 ad libitum (Velas, Lysa´
nad Labem, Czech Republic). In accordance with Czech
legislation, all animals received care according to the
guidelines set out by the Institutional Animal Use and Care
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Committee of the Faculty of Medicine of Hradec Kra´love´,
and this committee approved our study.
The animals were selected for laparotomy (LAP, sham
operation) or 2/3 partial hepatectomy (PHx) under ether
anesthesia [7]. Water for injections (AI) or EGCG in a dose
of 20 or 50 mg/kg body weight was administered intra-
peritoneally for 3 consecutive days (regimen according to
[15]), with the third dose administered immediately after
the operation. The animals were divided into following five
groups:
I—AI ? LAP: water for injections and laparotomy,
n = 6;
II—EGCG50 ? LAP: EGCG 50 mg/kg and laparot-
omy, n = 6;
III—AI ? PHx: water for injections and PHx, n = 6;
IV—EGCG20 ? PHx: EGCG 20 mg/kg and PHx,
n = 6;
V—EGCG50 ? PHx: EGCG 50 mg/kg and PHx,
n = 6.
The animals were killed under general general anes-
thesia by exsanguination 24 h after the operation, i.e., on
the 4th day of the experiment. BrdU for detection of DNA
synthesis was administered at a dose of 50 mg/kg intra-
peritoneally 1 h before sacrificing. Blood and liver samples
were immediately frozen in liquid nitrogen and stored at
-80 C until analysis. Resected liver from the 3rd day and
the remnant on the 4th day were weighed and liver growth
was calculated according to formulas from the literature
[25, 26].
Serum Biochemical Measurements
Serum concentrations of glucose, total and conjugated
bilirubin, activities of alanine aminotransferase (ALT),
aspartate aminotransferase (AST) and alkaline phosphatase
(ALP) of all animals were measured in the Department of
Clinical Biochemistry and Diagnostics, University Hospital
in Hradec Kra´love´. In the hepatectomized groups (groups
III, IV, V), plasmatic levels of malondialdehyde (MDA)
were also measured.
Determination of GSH and GSSG
After adding the liver homogenate to cold 10 % meta-
phosphoric acid, mixing and centrifuging (20,0009g,
10 min., 4 C), glutathione in the supernatant was analyzed
by Hissin’s fluorimetric method [27] modified by Rousˇar
[28]. Briefly, GSH was exposed to orthophthalaldehyde in
hydrogenphosphate buffer, and the fluorimetric detection
was carried out (kEx = 340 nm, kEm = 420 nm). GSSG
was assessed after alkaline hydrolysis in the same way as
GSH.
Determination of Liver Tissue Cytokines and TBARS
The protein content in the sample was determined after
homogenization in RIPA buffer and spinning (10,0009g)
by the Bradford method [29] using bovine serum albumin
as a standard. Afterwards, levels of liver TNF-a in the
supernatant were measured using the ELISA method. Rat
TNF-alpha Platinum ELISA, Rat IL-1 beta Platinum
ELISA and Rat TGF-beta1 Platinum ELISA kits were
purchased from eBioscience (San Diego, CA, USA).
Lipid peroxidation in liver supernatants from the
homogenates was determined according to Ohkawa et al.
[30], i.e., by the assessment of thio barbituric acid reactive
substances (TBARS).
Determination of Caspase-3/7 Activity in Liver
Homogenate
Activity of executive caspases was measured using the Cas-
pase-GloTM 3/7 kit. Briefly, after homogenization according
to Liu et al. [31], the tissues were centrifuged and samples
adjusted to contain the same amount of protein [29]. The
samples were incubated for 1 and 2 h with Caspase-GloTM
reagent (contains substrate for caspases 3/7), and the emitted
luminescence was measured using the TECAN Infinite M200.
Determination of p21, p-p27, p-p53, and Bcl-2
Expression
Expression of p21, p-p27 and p-p53 genes at the protein level
was estimated using the Western blot method as described
previously [32]. After homogenization [31] and quantifica-
tion of protein content [29], the lysates containing an equal
amount of protein (10 lg) were subjected to SDS-PAGE
using gradient gel NuPAGE Novex Bis–Tris Mini gels
4–12 % (Life Technologies, Carlsbad, CA, USA) and
transferred to a cellulose nitrate membrane (Bio-Rad Lab-
oratories, Hercules, CA, USA). The membranes were incu-
bated with primary rabbit antibodies at 4 C overnight and
with secondary antibody goat anti-rabbit IgG for 2 h. Pro-
teins were visualized using a chemiluminescence detection
kit (Roche, Penzberg, Germany) and autoradiographic film
(Foma, Hradec Kralove, Czech Republic). To confirm equal
protein loading, each membrane was reprobed and reincu-
bated to detect b-actin. The preparation differed for Bcl-2
protein, where we used a more concentrated homogenate of
liver tissue in RIPA buffer.
Determination of HO-1 and Nqo-1 Gene Expression
Gene expression was examined as previously described
[33], with the exception that total RNA from liver tissue
was isolated by phenol–chloroform extraction using the
978 Dig Dis Sci (2014) 59:976–985
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RNA Blue kit (TOP-Bio, Prague, Czech Republic). Taq-
Man Fast Universal PCR Master Mix and pre-designed
TaqMan Gene Expression Assay kits were from Life
Technologies (Carlsbad, CA, USA), and primers and probe
were purchased from Generi Biotech (Hradec Kra´love´,
Czech Republic). Glyceraldehyde-3-phosphate dehydro-
genase was used as reference for normalizing the data.
Liver Histology, Incorporation of Bromodeoxyuridine
After the rats had been killed, liver samples were immedi-
ately fixed by immersion in 4 % neutral formaldehyde.
Paraffin sections were stained with hematoxylin & eosin and
checked for the presence of steatosis and/or inflammation.
Furthermore, apoptosis was assessed according to [34], i.e.,
the number of apoptotic bodies per visual filed was calcu-
lated in hematoxylin & eosin-stained samples. The pathol-
ogist evaluating the samples was blinded to the study.
The immunohistochemical analysis was made on par-
affin sections of the liver tissue as described previously
[35]. Briefly, the paraffin sections were incubated with
primary mouse anti-BrdU monoclonal antibody, then with
biotinylated anti-mouse secondary antibody and subse-
quently with a streptavidin conjugate of peroxidase (Dako,
Glostrup, Denmark). Visualization of bound antibody was
performed using 3,30-diaminobenzidine-tetrahydrochloride
and hydrogen peroxide. BrdU incorporation was deter-
mined by counting of positively stained hepatocyte nuclei
in nine representative microscope fields (9100 magnifica-
tion) using an Olympus IX51 microscope and quantified
using a computer-aided image analysis system NIS-Ele-
ments AR 2.30 (Nikon, Lewisville, TX, USA).
Statistical Analysis
The results are expressed as the mean ± SD. Analyses
were performed using Graph-Pad Prism 4.03 software
(Graph Pad Software, San Diego, CA, USA). First, nor-
mality was tested by Kolmogorov-Smirnov test. In normal
data, comparisons were made among the groups using
ANOVA followed by Tukey-Kramer’s post hoc test. In the
case of non-Gaussian distribution, non-parametric Kruskal-
Wallis tests and Dunn’s post hoc test were used. p \0.05
was considered statistically significant.
Results
Animals, Body and Liver Weight
During our experiment all animals survived until the sac-
rifice. One animal from the EGCG50 ? PHx group had a
surgical complication (hemoperitoneum) and was excluded
from further analysis. In group I (AI ? LAP) the body
weight rose after the operation (p \ 0.05); in all other
groups, there was a non-significant trend to decline in body
weight after the operation. Body weight at operation did
not differ among groups; however, body weight was higher
at sacrifice in the AI ? LAP group when compared to the
EGCG50 ? LAP and AI ? PHx groups (p \ 0.001)
(Fig. 1).
Among hepatectomized groups (III, IV, V), the calcu-
lated indices of liver regeneration appeared highest in the
EGCG20 ? PHx group; however, due to high variability
the differences were not statistically significant (Table 1).
Histological Findings, Incorporation of BrdU
In hematoxylin & eosin staining from the caudate lobe,
distinct lipid accumulation was visible in the hepatecto-
mized groups (III, IV, V); this is consistent with published
Fig. 1 Body weight of experimental animals at operation (day 1) and
at sacrifice (day 2). §, §§, §§§When comparing the same group at
sacrifice and at operation. , , When comparing the EGC-
G50 ? LAP group with the AI ? LAP group; *, **, *** when
compared to laparotomized animals (AI ? PHx vs. AI ? LAP;
EGCG20 ? PHx vs. EGCG50 ? LAP; EGCG50 ? PHx vs. EGC-
G50 ? LAP), p \ 0.05; p \ 0.01; p \ 0.001, respectively
Table 1 Indices of liver regeneration





HRR (%) 9.5 ± 4 13.5 ± 6 8.9 ± 10 ns
LRR (%) 23.3 ± 8 29.9 ± 9 18.1 ± 25 ns
HRR (%) = (C - (A - B))/A 9 100 (Murata [26])
LRR (%) = (C - (A - B))/C 9 100 (Selzner [25])
A estimated total liver weight at PHx, B excised liver weight,
C weight of regenerated liver at sacrifice
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data [36]. In addition, there was vacuolation of the cyto-
plasm in peripherally located hepatocytes in the hepatec-
tomized groups and sporadically occurring pyknotic nuclei.
In the center of the lobe, sparse hepatocytes with granular
eosinophilic cytoplasm occurred. We did not observe signs
of pronounced inflammatory infiltration in any of the rats.
The number of apoptotic bodies was significantly higher in
the hepatectomized groups (III, IV, V) compared to the
laparotomized groups (I, II). The apoptotic bodies were
mostly noticed around the central veins. The laparotomized
groups did not differ from one another in apoptotic body
count; we did not observe differences among the hepatec-
tomized animals either (Fig. 2e).
Immunohistochemical staining for incorporated BrdU
showed only sporadic positive hepatocytes in the laparo-
tomized groups (I, II); there was high positivity in the
hepatectomized groups (III, IV, V). We observed no dif-
ference between groups III and IV; however, the count of
BrdU-positive cells in the EGCG50 ? PHx group was
lower when compared to the AI ? PHx and
Fig. 2 a DNA synthesis
estimated by BrdU
incorporation. *, **, *** When
compared to laparotomized
animals (AI ? PHx vs.
AI ? LAP; EGCG20 ? PHx
vs. EGCG50 ? LAP;
EGCG50 ? PHx vs.
EGCG50 ? LAP); ?, ??,
???when compared to the
AI ? PHx group; 9, 99,
999when compared to the
EGCG20 ? PHx group,
p \ 0.05; p \ 0.01; p \ 0.001,
respectively. b Laparotomized
groups: only sporadic BrdU-
positive cells. c Group III
(AI ? PHx): numerous BrdU-
positive cells. d Group V
(EGCG50 ? PHx): numerous
BrdU-positive cells, but less
than in groups III and IV. Note
that the positive nuclei are
mostly in periportal areas.
e Apoptotic bodies. *, **, ***
When compared to
laparotomized animals
(AI ? PHx vs. AI ? LAP;
EGCG20 ? PHx vs.
EGCG50 ? LAP;
EGCG50 ? PHx vs.
EGCG50 ? LAP)
980 Dig Dis Sci (2014) 59:976–985
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EGCG20 ? PHx groups (p \ 0.001 for both comparisons)
(Fig. 2a–d). BrdU positivity and thus DNA synthesis were
noticed mostly in the periportal areas (Fig. 2c–d).
Serum Biochemical Characteristics
Serum glycemia was higher in group II (EGCG50 ? LAP)
when compared to group I (AI ? LAP). There was a trend
towards hyperglycemia even at a dose of 20 mg/kg when
comparing group IV (EGCG20 ? PHx) with group III
(AI ? PHx). In addition, we observed lower glycemia in
the hepatectomized groups treated with EGCG when
compared to the EGCG50 ? LAP group.
Alanine aminotransferase and aspartate aminotransferase
activity was higher in hepatectomized animals, but the statis-
tical significance was present only when comparing
EGCG20 ? PHx and EGCG50 ? PHx with EGC-
G50 ? LAP. Furthermore, the ALT and AST activity was
somewhat lower in the EGCG20 ? PHx than in the AI ? PHx
group, but this difference did not reach statistical significance.
Alkaline phosphatase activity was higher in all hepatectomized
groups when compared to the laparotomized groups.
Total bilirubin was higher in the EGCG50 ? LAP group
than in the AI ? LAP group, and in the hepatectomized
than in the laparotomized groups; however, a significant
difference was observed only when comparing the
AI ? PHx with the AI ? LAP groups. Conjugated biliru-
bin was higher in the hepatectomized than in the laparo-
tomized groups, reaching significance only when
comparing the EGCG50 ? PHx with the EGCG50 ? LAP
group. Both total and conjugated bilirubin reached their
highest values in the EGCG50 ? PHx group; however, the
differences among hepatectomized groups were not statis-
tically significant (Table 2).
Tissue Cytokines TNF-a, IL-6, and TGF-b: Markers
of Oxidative Stress
We observed an insignificant trend of lower TNF-a in
hepatectomized groups treated with EGCG when compared
to the AI ? PHx group. A similar trend was observed with
IL-6, and its expression was significantly lower in the
EGCG50 ? PHx group when compared to the AI ? PHx
group (Fig. 3). We did not observe differences in the
expression of liver TGF-b1.
A similar non-significant trend of lower tissue MDA,
GSH and GSSG content as well as lower plasmatic MDA
was observed in the EGCG20 ? PHx group when com-
pared to the AI ? PHx and EGCG50 ? PHx groups;
however, none of these reached the level of statistical
significance (Table 3).
Nqo-1 and HO-1 Gene Expression at the mRNA Level
There were no significant differences among hepatecto-
mized groups in mRNA expression of Nqo-1 and HO-1.
Because of the small amount of measured samples in
experimental groups (n = 3), we observed only an insig-
nificant trend of lower HO-1 expression in
EGCG20 ? PHx and higher HO-1 expression in the
Table 2 Serum biochemistry
AI ? LAP EGCG 50 ? LAP AI ? PHx EGCG 20 ? PHx EGCG 50 ? PHx p value
Glycemia (mmol/l) 7.01 ± 0.61 10.49 ± 0.28 7.97 ± 0.57 8.9 ± 0.69* 8.71 ± 0.75* \0.001
ALT (lkat/l) 1.01 ± 0.57 0.64 ± 0.06 4.08 ± 4.76 2.7 ± 1.38** 5.44 ± 4.95** \0.01
AST (lkat/l) 3.2 ± 1.99 1.89 ± 0.37 7.05 ± 6.34 6.33 ± 2.57** 9.92 ± 8.20** \0.01
ALP (lkat/l) 2.4 ± 0.45 2.57 ± 0.32 7.08 ± 1.11*** 6.8 ± 1.29*** 6.61 ± 1.39*** \0.001
Bilirubin total (lmol/l) 2.0 ± 0.0 3.0 ± 0.0 4.0 ± 1.55* 3.5 ± 0.55 5.6 ± 2.19 \0.05
Bilirubin conj. (lmol/l) 1.83 ± 0.41 2.0 ± 0.0 2.6 ± 0.89 2.17 ± 0.41 4.2 ± 2.28* \0.05
, , When comparing the EGCG50 ? LAP with the AI ? LAP group
*, **, *** When compared to laparotomized animals (AI ? PHx vs. AI ? LAP; EGCG20 ? PHx vs. EGCG50 ? LAP; EGCG50 ? PHx vs.
EGCG50 ? LAP), p \ 0.05; p \ 0.01; p \ 0.001, respectively
Fig. 3 Tissue levels of IL-6. ?, ??, ???When compared to the
AI ? PHx group, p \ 0.05; p \ 0.01; p \ 0.001, respectively
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EGCG50 ? PHx group when compared to the AI ? PHx
group (not shown).
Activity of Caspases 3/7
After 1 h incubation, lower activity in the EGCG50 ? PHx
group was observed when compared to the AI ? PHx and
EGCG20 ? PHx groups (p \ 0.01 for both comparisons).
After 2 h incubation, the EGCG50 ? PHx group also had
lower activity compared to both the AI ? PHx (p \ 0.05)
and EGCG20 ? PHx (p \ 0.001) groups (Fig. 4).
Protein Expression of Cell-Cycle Regulating Proteins
Protein expression of p21 and p-p27 did not differ among
hepatectomized groups. On the other hand, expression of
p-p53 protein appeared higher in group IV
(EGCG20 ? PHx) and lower in group V (EGCG50 ? PHx)
than in group III (AI ? PHx) (Fig. 5). We were not able to
detect Bcl-2 protein.
Discussion
Despite several studies describing the beneficial effect of
EGCG on the liver in various experimental models, there
was no beneficial effect on liver regeneration after PHx in
our experiment. There was even lower DNA synthesis in
animals receiving higher doses of EGCG. Based on our
results, the use of EGCG in conditions of organ alteration,
such as regenerating liver, cannot be recommended. The
effect of EGCG is complex: several hundred EGCG-reg-
ulated genes were identified in a study with microarrays
[37]. Furthermore, anti-proliferative and -cancer properties
of EGCG are known [38, 39].
Since EGCG was reported to decrease the production
of TNF-a [40] and IL-6 [38], which plays an important
role in liver regeneration [41, 42], we wondered if the
inhibiting effect of EGCG on DNA synthesis was medi-
ated in this way. There was only a non-significant trend of
lower TNF-a levels in EGCG-treated hepatectomized
animals when compared to hepatectomized animals
receiving water for injections. A possible explanation is
that TNF-a is involved in regulation of even earlier
events in liver regeneration [24]. Similarly, the levels of
IL-6 were lower in the EGCG50 ? PHx group compared
to the AI ? PHx group.
Furthermore, EGCG was repeatedly reported to activate
caspases and increase apoptosis [43–46]. Surprisingly, we
found rather lower activity of executive caspases 3/7 in
liver homogenates from group V (EGCG50 ? PHx) than
from animals receiving a lower dose (EGCG20 ? PHx) or
vehicle only (AI ? PHx). An explanation could be the
different effects of EGCG on tumor and normal cells:
EGCG was shown to protect hepatocytes from apoptosis
caused by toxic injury [47, 48]. Direct inhibition of caspase
3 by EGCG was also described [49]. We were not able to
detect the Bcl-2 protein using Western blot. However, we
are not the first workplace to fail to do so: Tzung et al. [50]
reported undetectable levels of Bcl-2 mRNA and protein at
24 h after PHx. Our results of apoptotic body count are also
in accord with [50], since the authors showed a peak of
Table 3 Cytokines TNF-a, IL-6 and TGF-b: markers of oxidative stress
AI ? PHx EGCG 20 ? PHx EGCG 50 ? PHx p value
Plasmatic MDA (lmol/l) 1.20 ± 0.18 1.07 ± 0.18 1.24 ± 0.14 ns
Tissue MDA (nmol/mg protein) 0.35 ± 0.20 0.27 ± 0.07 0.47 ± 0.13 ns
Tissue GSH (lmol/l) 810 ± 195 717 ± 164 781 ± 144 ns
Tissue GSSG (lmol/l) 238 ± 169 188 ± 140 241 ± 164 ns
Tissue TNF-a (pg/ml) 803 ± 103 771 ± 69 752 ± 126 ns
Tissue IL-6 (pg/ml) 785 ± 122 686 ± 111 660 ± 99? \0.05
Tissue TGF-b1 (pg/ml) 8,024 ± 4,775 6,340 ± 4,053 7,647 ± 4,651 ns
?, ??, ??? When comparing the EGCG50 ? PHx with the AI ? PHx group, p \ 0.05; p \ 0.01; p \ 0.001, respectively
Fig. 4 Activity of executive caspases 3/7; incubation for 1 and 2 h,
respectively. ?, ??, ???When compared to the AI ? PHx group; 9,
99, 999when compared to the EGCG20 ? PHx group, p \ 0.05;
p \ 0.01; p \ 0.001, respectively
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high proapoptotic Bad and rather lower expression of
antiapoptotic Bcl-x at 24 h after PHx.
Other antiproliferative mechanisms of EGCG are
changes in cell-cycle regulating proteins, especially
induction of cyclin-dependent kinase inhibitors p21 and
p27 [43, 51, 52], and increased expression and serine
phosphorylation of p53 [45, 53]. However, we were not
able to prove a difference in p21 and p27 expression among
hepatectomized groups. Expressions of phosphorylated p53
appeared higher in the EGCG20 ? PHx group and sur-
prisingly lower in hepatectomized animals receiving a
higher dose of EGCG (EGCG50 ? PHx) when compared
to the group receiving vehicle (AI ? PHx).
Many more antiproliferative mechanisms of EGCG
were described, changes in protein kinases, growth factors
and transcription factors [38], e.g., inhibition of NF-KB
[54].
To check whether the Nrf2 pathway had been activated,
we measured the expression of HO-1 and Nqo-1 genes,
which belong to Nrf2 effectors, at the mRNA level [55,
56]. However, due to the small number of samples, we
were not able to prove activation of this pathway.
Interestingly, EGCG led to higher glycemia compared to
vehicle-treated rats, which is in contrary to other findings
[22, 23]. It should be mentioned that orally administered
EGCG decreases glucose absorption from the intestine, but
parenterally administered EGCG hinders glucose uptake
into the tissues [57].
Although some antioxidants accelerated liver regenera-
tion after PHx, as could be seen in a study with vitamin C
and E [11], and a study with bicyclol [58], other antioxi-
dants and hepatoprotective agents revealed a rather inhib-
itory effect on liver regeneration after PHx, namely
resveratrol [59], curcumin [60] and S-adenosylmethionin
[61]. Considering the often complex effect of natural
antioxidants on cells, the diversity of the results is not
surprising. Similarly, the immunosuppressant sirolimus
was able to attenuate ischemia–reperfusion injury, but
impaired liver regeneration after PHx [62].
Not only our results, but also other studies suggest that
EGCG should be used with caution. EGCG is present in over-
the-counter extracts from green tea [63, 64] and even in other
herbal dietary supplements that do not indicate content of
catechins [65]. These supplements are not without a risk—
there were repeatedly reported cases of acute liver injury
caused by green tea extracts [66–68]. Although these injuries
can be partly explained by toxicity of other substances in the
supplements (especially caffeine and/or undetected con-
taminants), EGCG itself also revealed important effects,
particularly interaction with other drugs [69, 70] and a pro-
oxidant effect at high doses [67, 71]. In mice, the dose of
120 mg/kg administered intraperitoneally was hepatotoxic
and the dose 150 mg/kg lethal for all mice [71]; the dose of
1,500 mg/kg via a gastric tube was lethal for 85 % of mice
[64]. In rats, the dose of 2,000 mg/kg administered via a
gastric tube was lethal. Recently, a cholestatic effect of
EGCG was described [72]; higher levels of conjugated bil-
irubin (even though not significantly) in EGCG-treated
animals in our study correspond to these findings.
In a study with healthy human volunteers, a single dose
of 1,600 mg EGCG taken orally was found to be safe and
well tolerated [73]. Potential application of EGCG in
clinical studies is complicated by hardly predictable bio-
availability [74].
In conclusion, administration of EGCG did not enhance
the early phase of liver regeneration after PHx in rats. The
higher dose even led to lower DNA synthesis. Although the
tests carried out have failed to clarify the mechanism of
this effect, it was probably mediated by some pathway
other than p53.
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